Simply Radiant

Radiant Biotherapeutics is a preclinical-stage biotechnology company developing a novel class of multi-valent, multi-specific antibody therapeutics using its proprietary Multabody™ platform. The platform leverages nature's protein scaffolding principles to create molecules with high avidity and the ability to engage multiple disease targets simultaneously, overcoming the limitations of traditional monoclonal and bispecific antibodies. Based on foundational research from the Hospital for Sick Children (SickKids) and the University of Toronto, the company is advancing a pipeline focused on oncology and infectious diseases. Radiant recently closed a $35 million Series A financing round in September 2024 to accelerate its lead programs toward clinical development.